Dapitant

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[3-[[2-(3,4-dichlorophenyl)acetyl]amino]-2-benzofuranyl]oxy]propanoic acid | image = Dapitant_structure.png | width = 200 | CAS_number = 153322-05-5 | ATC_prefix = none | PubChem = 9578570 | ChemSpiderID = 7854510 | UNII = 3F0K4U5QF6 | KEGG = D07865 | ChEMBL = 2103870 | C=19 | H=15 | Cl=2 | N=1 | O=5 | smiles = C1=CC(=C(C=C1C(=O)C2=CC=CO2)Cl)Cl.CC(C(=O)O)OC3=CC=CC=C3NC(=O)C4=CC=CO4 }}

Dapitant is a chemical compound that acts as a selective antagonist of the neurokinin-1 (NK1) receptor. It has been studied for its potential therapeutic effects in various conditions, including pain management and psychiatric disorders.

Pharmacology

Dapitant is a member of the class of compounds known as neurokinin receptor antagonists. These compounds work by blocking the action of substance P, a neuropeptide that binds to the NK1 receptor. Substance P is involved in the transmission of pain and other sensory signals, as well as in the regulation of mood and anxiety.

Mechanism of Action

Dapitant binds to the NK1 receptor, preventing substance P from activating the receptor. This blockade can lead to a reduction in pain perception and has been investigated for its potential to treat conditions such as chronic pain, depression, and anxiety disorders.

Clinical Research

Dapitant has been the subject of various clinical trials to assess its efficacy and safety. While initial studies showed promise, further research is needed to fully understand its therapeutic potential and to determine the optimal dosing regimens.

Pain Management

In studies related to pain management, dapitant has been evaluated for its ability to reduce pain in conditions such as migraine and osteoarthritis. The results have been mixed, with some studies showing significant pain relief and others showing minimal effects.

Psychiatric Disorders

Dapitant has also been explored as a treatment for psychiatric disorders, particularly those involving mood and anxiety. The blockade of NK1 receptors may help alleviate symptoms of depression and generalized anxiety disorder.

Side Effects

The side effects of dapitant are generally mild but can include nausea, dizziness, and fatigue. As with any medication, the risk of side effects must be weighed against the potential benefits.

Regulatory Status

As of the latest updates, dapitant has not been approved by major regulatory agencies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any specific indications. Research is ongoing to determine its potential applications and safety profile.

Also see

• Neurokinin receptor antagonist
• Substance P
• Pain management
• Depression treatment
• Anxiety disorder